Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex32.htm |
| EX-31.2 - EX-31.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex312.htm |
| EX-31.1 - EX-31.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex311.htm |
| EX-23.1 - EX-23.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex231.htm |
| EX-21 - EX-21 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex21.htm |
| EX-10.18 - EX-10.18 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex1018.htm |
| EX-3.1 - EX-3.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex31.htm |
| 10-K - FORM 10-K - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943d10k.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
Provectus Biopharmaceuticals, Inc.
Knoxville, Tennessee
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-205704) of Provectus Biopharmaceuticals, Inc. of our report dated March 30, 2016 relating to the 2015 and 2014 consolidated financial statements, which appear in this Form 10-K.
| /s/ BDO USA, LLP |
| Chicago, Illinois |
| March 31, 2017 |